2017 American Transplant Congress
Circulating Donor-Specific Anti-HLA Antibodies Accelerate the Progression of Interstitial Fibrosis in Kidney Allografts.
Paris Translational Research Center for Organ Transplantation, Paris, France
Interstitial fibrosis represents a major cause of kidney allograft failure. Addressing the causes of accelerated ageing of kidney allografts represents an important challenge to improve…2017 American Transplant Congress
Belatacept for Chronic Antibody-Mediated Rejection in Kidney Transplantation.
Background: Chronic antibody mediated rejection (cAMR) is a major cause of long-term kidney transplant (KT) loss. Antibody or immune cell depletional therapies have unclear efficacy…2017 American Transplant Congress
Outcomes with Kidney Transplant from Deceased Donors with Acute Kidney Injury and Prolonged Cold Ischemia Time: UNOS Analysis.
Nephrology, Columbia University Medical Center, New York, NY
Longer cold ischemia time (CIT) is associated with an increased risk of delayed graft function and may increase the risk of graft failure. Kidneys with…2017 American Transplant Congress
Kidney Transplant Recipient Intermediate and Long Term Outcomes for Living Donor Gifted Lithiasis.
Indiana University Health, Indianapolis
BACKGROUND: Nephrolithiasis is considered at least a relative contraindication to living donor nephrectomy due to the potential for adverse outcomes of recurrence, obstruction and infection.…2017 American Transplant Congress
C5b-9 Deposition in Glomerular Capillaries Is Responsible for Poor Allograft Survival in Antibody-Mediated Rejection.
1University Hospital, Montpellier, France; 2Cancer Research Institute, Montpellier, France
Introduction: C4d (scare of C4 cleavage) deposition in peritubular capillaries (PTC), a marker of complement activation, is associated with antibody-mediated rejection (AMR) in kidney transplantation.…2017 American Transplant Congress
Current Status of HIV-to-HIV Transplants in the United States.
1JHU, Baltimore, MD; 2Mount Sinai, New York, NY; 3NIH, Bethesda, MD; 4NYU, New York, NY
The HIV Organ Policy Equity (HOPE) Act allows transplantation using organs from HIV-infected (HIV+) donors for HIV+ individuals in the United States under research protocols.…2017 American Transplant Congress
Dialysis Facility Providers' Awareness of Racial Disparities in Kidney Transplantation.
Background Racial disparities persist in access to kidney transplant (KTx) in the US, where African Americans (AAs) have lower rates of waitlisting than whites. Despite…2017 American Transplant Congress
A Novel Belatacept Regimen to Optimize Efficacy and Safety.
1MGH, Boston; 2UCSF, San Francisco
Despite superior long term graft survival when compared to cyclosporine, the use of the FDA approved belatacept regimen in clinical practice has been constrained by…2017 American Transplant Congress
Regulatory T Cells Inhibit Plasmablast Formation and IgG Production by Tempering T Follicular Helper Cell Function.
Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA
Background: Donor-specific antibodies (DSA) are an important biomarker for acute rejection, transplant glomerulopathy and late allograft failure in kidney transplantation. Few studies have characterized the…2017 American Transplant Congress
Prognostic Tools to Choose Candidates for Successful Desensitization.
1Northwestern University, Chicago, IL; 2Johns Hopkins, Baltimore, MD
Antibodies to donor HLA antigens are a barrier to solid organ transplantation. Strategies to desensitize patients have improved, but the ability to predict response to…
- « Previous Page
- 1
- …
- 348
- 349
- 350
- 351
- 352
- …
- 531
- Next Page »